These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 28787714)

  • 21. Immunotherapy for Alzheimer's disease.
    Gelinas DS; DaSilva K; Fenili D; St George-Hyslop P; McLaurin J
    Proc Natl Acad Sci U S A; 2004 Oct; 101 Suppl 2(Suppl 2):14657-62. PubMed ID: 15297619
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Co-immunization with DNA and protein mixture: a safe and efficacious immunotherapeutic strategy for Alzheimer's disease in PDAPP mice.
    Liu S; Shi D; Wang HC; Yu YZ; Xu Q; Sun ZW
    Sci Rep; 2015 Jan; 5():7771. PubMed ID: 25586780
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Anti-Abeta42- and anti-Abeta40-specific mAbs attenuate amyloid deposition in an Alzheimer disease mouse model.
    Levites Y; Das P; Price RW; Rochette MJ; Kostura LA; McGowan EM; Murphy MP; Golde TE
    J Clin Invest; 2006 Jan; 116(1):193-201. PubMed ID: 16341263
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Immunotherapy for Alzheimer's disease].
    Falkentoft AC; Hasselbalch SG
    Ugeskr Laeger; 2016 Jan; 178(3):V07150588. PubMed ID: 26815584
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Engineered antibody approaches for Alzheimer's disease immunotherapy.
    Robert R; Wark KL
    Arch Biochem Biophys; 2012 Oct; 526(2):132-8. PubMed ID: 22475448
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical trials of amyloid-based immunotherapy for Alzheimer's disease: end of beginning or beginning of end?
    Li Y; Liu Y; Wang Z; Jiang Y
    Expert Opin Biol Ther; 2013 Nov; 13(11):1515-22. PubMed ID: 24053611
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antibody-based therapy in Alzheimer's disease.
    Pul R; Dodel R; Stangel M
    Expert Opin Biol Ther; 2011 Mar; 11(3):343-57. PubMed ID: 21261567
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of a DNA Aβ42 Vaccine in Aged NZW Rabbits: Antibody Kinetics and Immune Profile after Intradermal Immunization with Full-Length DNA Aβ42 Trimer.
    Lambracht-Washington D; Fu M; Wight-Carter M; Riegel M; Rosenberg RN
    J Alzheimers Dis; 2017; 57(1):97-112. PubMed ID: 28222511
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunotherapeutic approaches for Alzheimer's disease.
    Wisniewski T; Goñi F
    Neuron; 2015 Mar; 85(6):1162-76. PubMed ID: 25789753
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Immunotherapy for Alzheimer's disease targeting Aβ].
    Tabira T
    Nihon Rinsho; 2016 Mar; 74(3):423-6. PubMed ID: 27025080
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antibody against C-terminal Abeta selectively elevates plasma Abeta.
    Gray AJ; Sakaguchi G; Shiratori C; Becker AG; LaFrancois J; Aisen PS; Duff K; Matsuoka Y
    Neuroreport; 2007 Feb; 18(3):293-6. PubMed ID: 17314674
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Targeting generation of antibodies specific to conformational epitopes of amyloid beta-derived neurotoxins.
    Lambert MP; Velasco PT; Viola KL; Klein WL
    CNS Neurol Disord Drug Targets; 2009 Mar; 8(1):65-81. PubMed ID: 19275637
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy of antibody-based therapies to treat Alzheimer's disease: just a matter of timing?
    Cedernaes J; Schiöth HB; Benedict C
    Exp Gerontol; 2014 Sep; 57():104-6. PubMed ID: 24835192
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Anti-amyloid beta to tau - based immunization: Developments in immunotherapy for Alzheimer disease.
    Lambracht-Washington D; Rosenberg RN
    Immunotargets Ther; 2013 Aug; 2013(2):105-114. PubMed ID: 24926455
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Amyloid-ß-directed immunotherapy for Alzheimer's disease.
    Lannfelt L; Relkin NR; Siemers ER
    J Intern Med; 2014 Mar; 275(3):284-95. PubMed ID: 24605809
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Passive immunization of the Abeta42(43) C-terminal-specific antibody BC05 in a mouse model of Alzheimer's disease.
    Asami-Odaka A; Obayashi-Adachi Y; Matsumoto Y; Takahashi H; Fukumoto H; Horiguchi T; Suzuki N; Shoji M
    Neurodegener Dis; 2005; 2(1):36-43. PubMed ID: 16909001
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunotherapy in Alzheimer's disease: do we have all the pieces of the puzzle?
    Sarazin M; Dorothée G; de Souza LC; Aucouturier P
    Biol Psychiatry; 2013 Sep; 74(5):329-32. PubMed ID: 23683656
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Aβ-Immunotherapeutic strategies: a wide range of approaches for Alzheimer's disease treatment.
    Montoliu-Gaya L; Villegas S
    Expert Rev Mol Med; 2016 Jun; 18():e13. PubMed ID: 27357999
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Development of Immunoassays for the Quantitative Assessment of Amyloid-β in the Presence of Therapeutic Antibody: Application to Pre-Clinical Studies.
    Bogstedt A; Groves M; Tan K; Narwal R; McFarlane M; Höglund K
    J Alzheimers Dis; 2015; 46(4):1091-101. PubMed ID: 26402635
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Decreased amyloid-β and increased neuronal hyperactivity by immunotherapy in Alzheimer's models.
    Busche MA; Grienberger C; Keskin AD; Song B; Neumann U; Staufenbiel M; Förstl H; Konnerth A
    Nat Neurosci; 2015 Dec; 18(12):1725-7. PubMed ID: 26551546
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.